Ulrich Specks
#145,496
Most Influential Person Now
Researcher
Ulrich Specks's AcademicInfluence.com Rankings
Download Badge
Physics
Why Is Ulrich Specks Influential?
(Suggest an Edit or Addition)Ulrich Specks's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. (2013) (4083)
- Rituximab versus cyclophosphamide for ANCA-associated vasculitis. (2010) (1810)
- Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. (1989) (696)
- Efficacy of remission-induction regimens for ANCA-associated vasculitis. (2013) (581)
- Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis (2017) (509)
- Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. (2005) (439)
- A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). (2001) (416)
- Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. (2006) (413)
- Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. (2003) (370)
- Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. (2001) (348)
- Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. (2015) (339)
- Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. (2020) (308)
- Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. (2003) (275)
- Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis (2017) (270)
- Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis (2007) (269)
- Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. (2012) (265)
- Lung toxicity associated with cyclophosphamide use. Two distinct patterns. (1996) (254)
- Anticytoplasmic autoantibodies in the diagnosis and follow-up of Wegener's granulomatosis. (1989) (252)
- Antineutrophil cytoplasmic antibodies. (1998) (245)
- Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. (2004) (241)
- ANCA-associated vasculitis (2020) (234)
- Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. (2010) (233)
- Rituximab treatment of idiopathic membranous nephropathy. (2008) (225)
- Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. (2011) (222)
- Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. (2006) (209)
- Integrin and Arg-Gly-Asp dependence of cell adhesion to the native and unfolded triple helix of collagen type VI. (1993) (205)
- ANCA-associated vasculitis — clinical utility of using ANCA specificity to classify patients (2016) (202)
- Cutaneous Wegener's granulomatosis: clinical, histopathologic, and immunopathologic features of thirty patients. (1994) (200)
- ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. (2007) (198)
- Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. (2004) (196)
- Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). (2005) (193)
- Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type (2015) (185)
- Diffuse alveolar hemorrhage syndromes. (2001) (177)
- Tracheobronchial involvement in Wegener's granulomatosis. (1995) (171)
- Brief Communication: High Incidence of Venous Thrombotic Events among Patients with Wegener Granulomatosis: The Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study (2005) (168)
- Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. (2011) (163)
- EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis (2010) (159)
- BAFF is elevated in serum of patients with Wegener's granulomatosis. (2005) (150)
- Pneumocystis pneumonia in patients treated with rituximab. (2013) (148)
- Cocaine-Induced Midline Destructive Lesions: Clinical, Radiographic, Histopathologic, and Serologic Features and their Differentiation from Wegener Granulomatosis (2001) (147)
- Brief Communication: High Incidence of Venous Thrombotic Events among Patients with Wegener Granulomatosis: The Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. (2005) (146)
- Structure of recombinant N‐terminal globule of type VI collagen alpha 3 chain and its binding to heparin and hyaluronan. (1992) (143)
- Idiopathic membranous nephropathy: diagnosis and treatment. (2008) (143)
- Wegener's granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s. (2002) (142)
- Exostosin 1/Exostosin 2-Associated Membranous Nephropathy. (2019) (140)
- Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. (2013) (136)
- An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's) (2013) (129)
- Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. (2008) (126)
- Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study. (2003) (125)
- European therapeutic trials in ANCA‐associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials EUROPEAN COMMUNITY STUDY GROUP ON CLINICAL TRIALS IN SYSTEMIC VASCULITIS ECSYSVASTRIAL (BMHl‐Cr93‐1078) (1995) (125)
- Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 (2016) (122)
- Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. (2015) (119)
- Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis (2017) (112)
- Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis (2011) (109)
- Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. (2013) (108)
- Neutrophil‐Related Gene Expression and Low‐Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2015) (106)
- Fibrosing Mediastinitis: Clinical Presentation, Therapeutic Outcomes, and Adaptive Immune Response (2011) (106)
- Increased expression of type VI collagen in lung fibrosis. (1995) (103)
- Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. (2005) (102)
- Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosupression. (2007) (99)
- Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. (2016) (99)
- Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. (2011) (99)
- Antineutrophil cytoplasmic antibodies. (1998) (97)
- Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement--a prospective, open-label pilot trial. (2010) (94)
- Airway involvement in Wegener's granulomatosis. (2007) (93)
- Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes (2015) (90)
- Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions. (2002) (86)
- Echocardiographic findings in patients with Wegener granulomatosis. (2005) (83)
- Sinonasal Osteocartilaginous Necrosis in Cocaine Abusers: Experience in 25 Patients (2003) (82)
- Cardiac Involvement in Granulomatosis with Polyangiitis (2015) (80)
- Update on diffuse alveolar hemorrhage and pulmonary vasculitis. (2012) (80)
- Melanoma antigen A4 is expressed in non-small cell lung cancers and promotes apoptosis. (2006) (80)
- Alpha₁-antitrypsin deficiency-related alleles Z and S and the risk of Wegener's granulomatosis. (2010) (80)
- Bronchoalveolar lavage fluid angiotensin-converting enzyme in interstitial lung diseases. (1990) (76)
- Expression of type VI collagen mRNA during wound healing. (1993) (76)
- Myeloperoxidase–Antineutrophil Cytoplasmic Antibody (ANCA)–Positive and ANCA‐Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets (2016) (74)
- Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's) (2011) (72)
- Capture-ELISA based on recombinant PR3 is sensitive for PR3-ANCA testing and allows detection of PR3 and PR3-ANCA/PR3 immunecomplexes. (1998) (72)
- Pulmonary involvement in Henoch-Schönlein purpura. (2004) (71)
- Outcome of patients with small-vessel vasculitis admitted to a medical ICU. (2007) (70)
- The Epidemiology of Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis in Olmsted County, Minnesota (2017) (69)
- Renal Transplantation in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Multicenter Experience (2011) (69)
- Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. (2019) (68)
- IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis (2011) (67)
- Cocaine-induced midline destructive lesions - an autoimmune disease? (2013) (65)
- Histopathologic Overlap between Fibrosing Mediastinitis and IgG4-Related Disease (2012) (64)
- Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial (2017) (64)
- Salivary gland involvement in Wegener's granulomatosis. (1991) (64)
- Pituitary dysfunction in granulomatosis with polyangiitis: the Mayo Clinic experience. (2014) (63)
- Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (2008) (63)
- Otorhinolaryngological manifestations in granulomatosis with polyangiitis (Wegener's). (2013) (62)
- Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis (2020) (62)
- The epidemiology of ANCA associated vasculitis in Olmsted County, Minnesota (USA): a 20 year population-based study (2017) (62)
- Differences between human proteinase 3 and neutrophil elastase and their murine homologues are relevant for murine model experiments (2005) (61)
- Immunohistochemical localization of collagen VI in diabetic glomeruli. (1994) (61)
- Risk of Cardiovascular Disease and Venous Thromboembolism Among Patients With Incident ANCA‐Associated Vasculitis: A 20‐Year Population‐Based Cohort Study (2018) (61)
- Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. (2011) (61)
- Granulomatous vasculitis. Wegener's granulomatosis and Churg-Strauss syndrome. (1990) (60)
- Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort. (2011) (60)
- Anti-neutrophil cytoplasmic antibodies. (1994) (59)
- Functional characterization of antineutrophil cytoplasmic antibodies in patients with cocaine-induced midline destructive lesions. (2008) (59)
- Interaction of proteinase 3 with CD11b/CD18 (β2integrin) on the cell membrane of human neutrophils (2003) (57)
- Pathogenesis of ANCA-Associated Vasculitis (2012) (55)
- Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis. (2017) (55)
- Successful pregnancy and delivery of a healthy newborn despite transplacental transfer of antimyeloperoxidase antibodies from a mother with microscopic polyangiitis. (2009) (55)
- Assessment of health‐related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's) (2012) (55)
- Granulomatosis with polyangiitis (Wegener's): An alternative name for Wegener's granulomatosis (2011) (54)
- Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. (2015) (54)
- The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event. (2007) (53)
- 2020 international consensus on ANCA testing beyond systemic vasculitis. (2020) (53)
- Recombinant human proteinase 3, the Wegener's autoantigen, expressed in HMC‐1 cells is enzymatically active and recognized by c‐ANCA (1996) (52)
- Rituximab for the Treatment of Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2014) (51)
- The future of damage assessment in vasculitis. (2007) (51)
- Long‐Term Follow‐up of Repair of External Nasal Deformities in Patients With Wegener's Granulomatosis (2002) (51)
- Cloning and functional expression of the murine homologue of proteinase 3: implications for the design of murine models of vasculitis (1997) (50)
- Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts. (2015) (50)
- Pulmonary necrotizing granulomas of unknown cause: clinical and pathologic analysis of 131 patients with completely resected nodules. (2013) (49)
- Different gender-associated genotype risks of Wegener's granulomatosis and microscopic polyangiitis. (2003) (48)
- Late breaking clinical trials 1 (2011) (48)
- Recombinant expression and properties of the Kunitz-type protease-inhibitor module from human type VI collagen alpha 3(VI) chain. (1994) (48)
- Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab (2012) (47)
- Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis. (2008) (47)
- Urinary Biomarkers in Relapsing Antineutrophil Cytoplasmic Antibody-associated Vasculitis (2013) (47)
- Primary Antiphospholipid Syndrome–Associated Diffuse Alveolar Hemorrhage (2014) (46)
- Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. (2005) (46)
- Antineutrophil cytoplasmic antibodies reacting with the pro form of proteinase 3 and disease activity in patients with Wegener's granulomatosis and microscopic polyangiitis. (2001) (46)
- Relationship Between Markers of Platelet Activation and Inflammation with Disease Activity in Wegener’s Granulomatosis (2011) (46)
- Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2018) (45)
- Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort. (2018) (44)
- A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis. (2005) (43)
- Churg-Strauss syndrome. (2006) (42)
- New Features of Disease After Diagnosis in 6 Forms of Systemic Vasculitis (2013) (41)
- Successful Induction of Remission With Rituximab for Relapse of ANCA‐Associated Vasculitis Post‐Kidney Transplant: Report of Two Cases (2007) (41)
- Does infection play a role in the pathogenesis of pulmonary vasculitis? (2003) (41)
- Cell adhesion to type-VI collagen. (1991) (40)
- Human mast cells expressing recombinant proteinase 3 (PR3) as substrate for clinical testing for anti‐neutrophil cytoplasmic antibodies (ANCA) (1997) (39)
- Diabetes insipidus and anterior pituitary insufficiency as presenting features of Wegener's granulomatosis. (2001) (39)
- Outcomes of Nonsevere Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Treated With Glucocorticoids (2015) (39)
- Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy (2016) (38)
- The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. (2018) (38)
- Serum Biomarkers in Patients with Relapsing Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss) (2015) (37)
- Targeting B lymphocytes in progressive fibrosing mediastinitis. (2014) (36)
- Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener's granulomatosis. (2008) (35)
- Anti-neutrophil cytoplasmic autoantibodies. (1988) (35)
- Role of testing for anticytoplasmic autoantibodies in the differential diagnosis of scleritis and orbital pseudotumor. (1990) (35)
- Meningeal involvement in Wegener granulomatosis. (2000) (34)
- Nasal biopsy in Wegener's granulomatosis. (1991) (34)
- Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis. (2018) (34)
- Clinical characteristics of inflammatory ocular disease in anti-neutrophil cytoplasmic antibody associated vasculitis: a retrospective cohort study (2017) (34)
- Meta-analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritis. (2012) (34)
- Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3–Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2017) (33)
- Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestations. (2007) (32)
- Discrimination and variable impact of ANCA binding to different surface epitopes on proteinase 3, the Wegener's autoantigen. (2010) (32)
- Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Renal Disease. (2020) (32)
- Are antineutrophil cytoplasmic antibodies pathogenic? Experimental approaches to understand the antineutrophil cytoplasmic antibody phenomenon. (2001) (31)
- Identification and phenotyping of circulating autoreactive proteinase 3-specific B cells in patients with PR3-ANCA associated vasculitis and healthy controls. (2017) (31)
- Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum. (2019) (31)
- Brief Report: The Value of a Patient Global Assessment of Disease Activity in Granulomatosis With Polyangiitis (Wegener's) (2014) (31)
- Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis. (2019) (31)
- Thromboembolism—Another Threat to the Polymorbid Patient with Vasculitis?: High Incidence of Venous Thrombotic Events among Patients with Wegener Granulomatosis: The Wegener’s Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med 142: 620–626, 2005 (2005) (31)
- What you should know about PR3-ANCA: Conformational requirements of proteinase 3 (PR3) for enzymatic activity and recognition by PR3-ANCA (2000) (29)
- Alpha 1 -Antitrypsin Deficiency–Related Alleles Z and S and the Risk of Wegener’s Granulomatosis (2011) (28)
- Mapping of Conformational Epitopes on Human Proteinase 3, the Autoantigen of Wegener’s Granulomatosis (2010) (27)
- Peripheral CD5+ B Cells in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2015) (27)
- Pulmonary…Henoch-Schönlein Purpura (2004) (27)
- International Consensus on ANCA Testing in Eosinophilic Granulomatosis with Polyangiitis. (2020) (25)
- A novel capture-ELISA for detection of anti-neutrophil cytoplasmic antibodies (ANCA) based on c-myc peptide recognition in carboxy-terminally tagged recombinant neutrophil serine proteases. (2005) (25)
- Methotrexate for Wegener's granulomatosis: what is the evidence? (2005) (25)
- Churg-Strauss syndrome: update on clinical, laboratory and therapeutic aspects. (2006) (24)
- Are animal models of vasculitis suitable tools? (2000) (24)
- Clinical utility of ANCA tests for the dermatologist (2003) (23)
- Inhibitors and Antibody Fragments as Potential Anti-Inflammatory Therapeutics Targeting Neutrophil Proteinase 3 in Human Disease (2016) (23)
- Wegener ’ s Granulomatosis : Survey of 701 Patients in North America . Changes in Outcome in the 1990 s (2004) (23)
- Interlobar variation in the recovery of bronchoalveolar lavage fluid, cell populations, and angiotensin-converting enzyme in normal volunteers. (1993) (23)
- Recombinant proteinase 3 produced in different expression systems: recognition by anti-PR3 antibodies. (2000) (23)
- Characterization of F-18 Fluorodeoxyglucose PET/CT in Granulomatosis with Polyangiitis. (2013) (23)
- Eosinophilic Granulomatosis with Polyangiitis: clinical predictors of long-term asthma severity. (2020) (22)
- The association of serum calprotectin (S100A8/S100A9) levels with disease relapses in PR3‐ANCA‐associated vasculitis (2016) (22)
- Wegener's granulomatosis in the 1990s--a pulmonary pathologist's perspective. (1993) (21)
- Accurate relapse prediction in ANCA-associated vasculitis-the search for the Holy Grail. (2015) (21)
- Design of the Rituximab in ANCA-Associated Vasculitis (RAVE) Trial (2011) (21)
- Circulating Angiopoietin-2 as a Biomarker in ANCA-Associated Vasculitis (2012) (21)
- Experience With Direct-to-Patient Recruitment for Enrollment Into a Clinical Trial in a Rare Disease: A Web-Based Study (2017) (21)
- Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2019) (21)
- The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2016) (21)
- Effects of carboxy-terminal modifications of proteinase 3 (PR3) on the recognition by PR3-ANCA. (2003) (20)
- Lesions of the respiratory tract associated with the finding of anti-neutrophil cytoplasmic autoantibodies with a perinuclear staining pattern. (1994) (20)
- Lung involvement in ANCA-associated vasculitis. (2019) (20)
- Hematopoietic Stem Cell Transplant-Membranous Nephropathy Is Associated with Protocadherin FAT1 (2022) (19)
- A Monoclonal Antibody (MCPR3-7) Interfering with the Activity of Proteinase 3 by an Allosteric Mechanism* (2013) (19)
- Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis. (2016) (19)
- Rituximab for the Treatment of Relapses in ANCA-associated Vasculitis (2014) (18)
- Agreement of anti‐neutrophil cytoplasmic antibody measurements obtained from serum and plasma (2006) (18)
- Biopsy‐proven pulmonary capillaritis: A retrospective study of aetiologies including an in‐depth look at isolated pulmonary capillaritis (2016) (18)
- Functional significance of Asn-linked glycosylation of proteinase 3 for enzymatic activity, processing, targeting, and recognition by anti-neutrophil cytoplasmic antibodies. (2006) (17)
- The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis. (2019) (17)
- Clinical trials in antineutrophil cytoplasmic antibody-associated vasculitis: what we have learnt so far, and what we still have to learn. (2017) (17)
- Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis (2019) (16)
- Pro: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab? (2015) (16)
- Severe/uncontrolled asthma and overall survival in atopic patients with eosinophilic granulomatosis with polyangiitis. (2018) (16)
- Isolated pauciimmune pulmonary capillaritis successfully treated with rituximab. (2015) (16)
- Extended Follow-up of Treatment with Rituximab Versus Cyclophosphamide for Remission-Induction of ANCA-Associated Vasculitis : Which Subsets Are At Greatest Risk for Flare? (2011) (16)
- Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis (2018) (16)
- The growing complexity of the pathology associated with cocaine use. (2011) (16)
- Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2019) (16)
- Efficacy of leflunomide in the treatment of vasculitis. (2020) (15)
- Wegener's granulomatosis presenting as multiple bilateral renal masses. (2004) (15)
- Coexistent Pulmonary Granulomatosis With Polyangiitis (Wegener Granulomatosis) and Crohn Disease (2014) (15)
- [Cocaine, ANCA, and Wegener's granulomatosis]. (2001) (15)
- Controversies in ANCA testing (2012) (14)
- Update on the Management of Respiratory Manifestations of the Antineutrophil Cytoplasmic Antibodies-Associated Vasculitides. (2019) (14)
- Implications of c-ANCA testing for the classification of Wegener's granulomatosis: performance of different detection systems. (1993) (14)
- Significance of antibodies to cytoplasmic components of neutrophils. (1989) (14)
- Targeting B lymphocytes as therapy for ANCA-associated vasculitis. (2007) (13)
- IgA antibodies to myeloperoxidase in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). (2017) (12)
- Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis (2017) (12)
- Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis (2017) (12)
- Kidney biopsy chronicity grading in antineutrophil cytoplasmic antibody-associated vasculitis (2021) (12)
- Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss Syndrome) (2014) (11)
- Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2017) (11)
- TNF-α Blocker Therapy and Solid Malignancy Risk in ANCA-Associated Vasculitis (2012) (11)
- A 70-year-old man with pulmonary infiltrates and a positive antineutrophil cytoplasmic autoantibody test result. (2005) (11)
- Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy (2022) (11)
- Clinical Manifestations and Long‐Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America (2021) (11)
- Antineutrophil cytoplasmic antibodies: are they pathogenic? (2004) (10)
- Can antineutrophil cytoplasmic antibody levels be used to inform treatment of pauci-immune vasculitis? (2015) (10)
- Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis (2014) (10)
- Comparison of disease activity measures for ANCA-associated vasculitis. (2004) (10)
- Plasma exchange for the management of ANCA-associated vasculitis: the con position. (2020) (10)
- Accuracy of the ICD-9 Code for Identification of Patients with Wegener’s Granulomatosis (2010) (10)
- Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma. (2019) (10)
- ANCA subsets: influence on disease phenotype. (2002) (10)
- Disease Activity, Glucocorticoid Exposure, and Rituximab Determine Body Composition Changes during Induction Treatment of ANCA‐Associated Vasculitis (2016) (9)
- Pulmonary capillaritis. (2004) (9)
- Role of Macrophage Migration Inhibitory Factor in Granulomatosis With Polyangiitis (2018) (9)
- Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab (2020) (9)
- Biologic agents in the treatment of granulomatosis with polyangiitis (2012) (8)
- Chronic rhinosinusitis in eosinophilic granulomatosis with polyangiitis: clinical presentation and antineutrophil cytoplasmic antibodies (2019) (8)
- Association of COVID‐19 antigenicity with the development of antineutrophilic cytoplasmic antibody vasculitis (2021) (8)
- Part 2: Synopsis of B-lymphocyte targeted therapy of ANCA-associated vasculitis. (2007) (8)
- Pulmonary Eosinophilic Granulomatosis with Polyangiitis has IgG4 Plasma Cells and Immunoregulatory Features. (2020) (8)
- Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis (2021) (7)
- Treatment of ANCA-associated vasculitis: new therapies and a look at old entities. (2014) (7)
- Immunoglobulin Concentrations and Infection Risk Among Patients with ANCA-Associated Vasculitis Treated with Rituximab or Cyclophosphamide. (2011) (7)
- Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis (2018) (7)
- Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis (2020) (7)
- Echocardiographic features of atrial myocarditis with giant cells: a case report. (2004) (7)
- Microtiter plate immunoassay for the evaluation of platelet adhesion to fibronectin. (1996) (7)
- Allosteric modulation of proteinase 3 activity by anti-neutrophil cytoplasmic antibodies in granulomatosis with polyangiitis. (2015) (7)
- Vasculitis: Will LAMP enlighten us about ANCA-associated vasculitis? (2012) (7)
- Epitope‐specific anti‐neutrophil cytoplasmic antibodies: Do they matter? Can they be detected? (2009) (6)
- Rituximab in Refractory Wegener's Granulomatosis: Favorable or Not? (2006) (6)
- Safety of remission induction with rituximab versus cyclophosphamide in patients 65 and older with severe ANCA-associated vasculitis (2013) (6)
- Current and Future Treatment Options for Eosinophilic Granulomatosis With Polyangiitis (2017) (6)
- S1. Rituximab for ANCA-associated vasculitis: the experience in the United States. (2013) (6)
- Cutaneous leukocytoclastic vasculitis with positive anti-neutrophil cytoplasmic antibodies. (1999) (6)
- Induction regimens for ANCA-Associated Vasculitis. (2013) (5)
- Comparison of neutrophil chemotactic factor release by human and rabbit alveolar macrophages in response to tannin exposure. (1995) (5)
- Efficacy Of Glucocorticoids To Treat Limited Flares In ANCA-Associated Vasculitis (2013) (5)
- Anti-neutrophil cytoplasmic autoantibodies (ANCA) against the murine homolog of proteinase 3 (Wegener’s autoantigen) are pathogenic in vivo Running heads: PFISTER et al, PATHOGENICITY OF PR3-SPECIFIC ANCA (2004) (5)
- LB01THE EFFECT OF PLASMA EXCHANGE ON END STAGE RENAL DISEASE AND DEATH IN PATIENTS WITH SEVERE ANCA ASSOCIATED VASCULITIS (2018) (5)
- Disease Activity, ANCA-Type, and Lipid Levels in ANCA-Associated Vasculitis. (2019) (5)
- Remote Activation of a Latent Epitope in an Autoantigen Decoded With Simulated B-Factors (2019) (5)
- An open-label trial of abatacept in mild relapsing granulomatosis with polyangiitis (Wegener's) (GPA) (2013) (5)
- Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis (2019) (5)
- Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2018) (5)
- Glycosylation of proteinase 3 (PR3) is not required for its reactivity with antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis. (2009) (5)
- Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis (2022) (5)
- Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis (2020) (4)
- Pleuritis and Pericarditis in ANCA-Associated Vasculitis. (2021) (4)
- Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited (2019) (4)
- Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission (2022) (4)
- Retreatment with Rituximab in the RAVE Trial (2013) (4)
- Epidemiology of Wegener granulomatosis since the introduction of ANCA testing in Olmsted County, MN, 1990-1999. (2003) (4)
- Serum Biomarkers of Disease Activity in Longitudinal Assessment of Patients with ANCA‐Associated Vasculitis (2021) (3)
- Cardiac Involvement in Wegener’s Granulomatosis: Echocardiographic Features and Clinical Outcomes (2002) (3)
- Vasculitis: Refining phenotypes in ANCA-associated vasculitis (2013) (3)
- The Incidence of Arterial and Venous Thrombosis in Antineutrophil Cytoplasmic Antibody–associated Vasculitis (2019) (3)
- 283. RADIOLOGIC AND PATHOLOGIC CHARACTERISTICS OF MYELOPEROXIDASE-ANTINEUTROPHIL CYTOPLASMIC ANTIBODY– ASSOCIATED INTERSTITIAL LUNG DISEASE: A RETROSPECTIVE ANALYSIS (2019) (3)
- Wegener's granulomatosis and pulmonary vasculitis (1995) (2)
- THU0436 Incidence, prevalence, mortality and chronic renal damage of anca-associated glomerulonephritis in a 20 year population-based cohort (2018) (2)
- Damage in ANCA-associated vasculitis: Preliminary evidence for the ANCA-associated vasculitis index of damage (AVID). (2006) (2)
- Autoreactive Plasmablasts After B Cell Depletion With Rituximab and Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2022) (2)
- Retreatment With Rituximab In The Rituximab In ANCA-Associated Vasculitis (RAVE) Trial (2013) (2)
- Prognosis of Wegener's granulomatosis limited to the respiratory tract: Significance of c-ANCA (1996) (2)
- Pulmonary Complications of Systemic Disease (1993) (2)
- B-lymphocyte targeted therapy for patients with progressive fibrosing mediastinitis (2014) (2)
- Preferential Binding of Anti-Neutrophil Cytoplasmic Antibodies to an Unexpected Epitope of a Chimeric Proteinase 3 Mutant (2019) (2)
- Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT. (2022) (2)
- PREVALENCE OF PLEURITIS AND PERICARDITIS IN ANCA-ASSOCIATED VASCULITIS (2018) (2)
- Risk factors for serious infections in ANCA-associated vasculitis (2023) (2)
- Membranous Nephropathy in Syphilis is Associated with Neuron-Derived Neurotrophic Factor (2023) (2)
- Remission maintenance in ANCA-associated vasculitis: does one size fit all? (2019) (2)
- Urine eosinophil‐derived neurotoxin: A potential marker of activity in select eosinophilic disorders (2022) (2)
- Comment on: Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum: reply. (2020) (2)
- Predicting Kidney Response to Plasma Exchange in ANCA-Associated Vasculitis: Need for Plausible Models. (2022) (2)
- OP0232 The Role of Baseline FCRL5 MRNA Expression in Predicting Response to Rituximab (RTX) Therapy in Patients with Granulomatous Polyangiitis (GPA) or Microscopic Polyangiitis (MPA) (2014) (2)
- 291. EFFICACY OF RITUXIMAB AND PLASMA EXCHANGE IN ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS WITH SEVERE RENAL DISEASE (2019) (2)
- The association of IgM ANCA with alveolar hemorrhage revisited (2013) (2)
- Granulomatosis with polyangiitis (Wegener's) is associated with HLA-DPB1*04 and EMA6A gene variants. Evidence from a genome-wide analysis (2013) (2)
- CARDIAC AND CEREBROVASCULAR MANIFESTATIONS OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (2019) (2)
- Rituximab Versus Cyclophosphamide for Central Nervous System Involvement of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Case Series. (2019) (2)
- Interstitial Lung Disease and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Two Villains Ganging Up On Patients. (2021) (2)
- Pathogenesis and Management of ANCA-Associated Vasculitis (2014) (2)
- RNA sequencing of idiopathic subglottic stenosis tissues uncovers putative profibrotic mechanisms and identifies a prognostic biomarker. (2022) (1)
- SaO038THE ASSOCIATION OF SERUM CALPROTECTIN (S100A8/A9) LEVELS WITH DISEASE RELAPSE IN PR3-ANCA ASSOCIATED VASCULITIS (2015) (1)
- Coexistent granulomatosis with polyangiitis (Wegener's) and Crohn disease: A clinicopathologic description of cases (2012) (1)
- 119. CARDIOVASCULAR AND VENOUS THROMBOEMBOLIC MANIFESTATIONS OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: A SINGLE CENTER SERIES OF 187 PATIENTS (2019) (1)
- Response to ‘Rituximab in membranous nephropathy’ (2008) (1)
- Diagnosing and treating ANCA-associated vasculitis: an updated review for clinical practice. (2022) (1)
- 222. PREFERENTIAL BINDING TO AN UNEXPECTED EPITOPE OF A CHIMERIC RECOMBINANT PROTEINASE 3 VARIANT BY ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES (2019) (1)
- MEPOLIZUMAB FOR THE TREATMENT OF PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: A PHASE III RANDOMISED, PLACEBO-CONTROLLED TRIAL (2017) (1)
- [Wegener's granulomatosis: systemic disease with preferential involvement of the respiratory tract]. (1989) (1)
- Pulmonary Manifestations of Vasculitis (2014) (1)
- 172. THE ASSOCIATION OF DIFFERENCES IN LIPID PARAMETERS WITH DISEASE ACTIVITY IN ANCA-ASSOCIATED VASCULITIS (AAV) (2019) (1)
- Damage in ANCA-associated vasculitis (2006) (1)
- A Rare Cause Hemoptysis Illustrating the Role of Single Ventricle Physiology in Bronchial Circulatio (2011) (1)
- Activation of a Latent Epitope Causing Differential Binding of Anti-Neutrophil Cytoplasmic Antibodies to Proteinase 3 (2022) (1)
- FRI0314 Different serum cytokine profiles reflect anti-neutrophil cytoplasmic antibodies (ANCA) specificity in patients with anca-associated vasculitis (2017) (1)
- Pleuritis and Pericarditis in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis (2021) (1)
- Predictive Value of Selected Markers of Inflammation and Platelet Activation for Complete Remission in ANCA-Associated Vasculitis (2012) (1)
- Do anticytoplasmic autoantibodies (ACPA) extend our understanding of the spectrum of Wegener's granulomatosis? (1990) (1)
- Pulmonary vasculitis: update on the management of ANCA-associated vasculitis (2009) (1)
- Chapter 59 – Pulmonary Vasculitis and Hemorrhage (2012) (1)
- The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition (2021) (1)
- 129. RESPIRATORY INVOLVEMENT IN PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: CLINICAL AND SEROLOGICAL PREDICTORS OF LONG-TERM ASTHMA SEVERITY (2019) (1)
- Pulmonary Low Attenuation Areas on CT in ANCA-associated Vasculitis: A quantitative and semi-quantitative analysis correlated with pulmonary function testing for obstructive airway disease (2020) (1)
- SP0007 Biologic Therapy in Anca-Associated Vasculitis: New Perspectives (2015) (1)
- Pulmonary Vasculitis and Alveolar Hemorrhage Syndromes (2009) (1)
- Pituitary dysfunction in granulomatosis with polyangiitis (2013) (1)
- Corrigendum to "Otorhinolaryngological manifestations in granulomatosis with polyangiitis (Wegener's)" [Autoimmun. Rev. 12 (2013) 501-505] doi 10.1016/j.autrev.2014.09.005 (2015) (1)
- Diffuse alveolar hemorrhage caused by primary antiphospholipid syndrome (2012) (1)
- Acquired cyclic neutropenia associated with cocaine‐induced anti‐neutrophil cytoplasmic antibodies binding to human neutrophil elastase (2018) (1)
- Prevalence of Venous Thromboembolism in Patients with Churg-Strauss Syndrome. (2009) (1)
- Insights from the ADVOCATE Study: Respiratory Tract Involvement in Patients with ANCA-Associated Vasculitis in a Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Avacopan (2022) (1)
- LB02THE EFFECT OF REDUCED-DOSE GLUCOCORTICOIDS DURING REMISSION INDUCTION IN SEVERE ANCA ASSOCIATED VASCULITIS (2018) (1)
- Improvement of constrictive bronchiolitis (bronchiolitis obliterans) after rituximab therapy in 2 patients with primary sjögren syndrome (2021) (1)
- Rituximab treatment of idiopathic membranous (2008) (1)
- Immunophenotyping of the Adaptive Immune Response in Fibrosing Mediastinitis. (2009) (0)
- A Transcriptomic Signature of Mepolizumab Response in Eosinophilic Granulomatosis With Polyangiitis (EGPA) (2023) (0)
- Proteomic profile of uninvolved versus crescentic glomeruli in MPO-ANCA-associated vasculitis (2023) (0)
- 167. PREVALENCE OF PLEURITIS AND PERICARDITIS IN ANCA-ASSOCIATED VASCULITIS (2019) (0)
- Corrigendum to “Cocaine-induced midline destructive lesions — an autoimmune disease?” [Autoimmun. Rev. 12 (2013) 496–500] (2015) (0)
- 045. EVALUATION OF NOVEL SERUM BIOMARKERS OF DISEASE ACTIVITY IN GIANT CELL ARTERITIS, TAKAYASU’S ARTERITIS, POLYARTERITIS NODOSA, AND EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (2019) (0)
- Vasculitis and Alveolar Hemorrhage (2020) (0)
- The value of a patient global assessment for disease activity in granulomatosis with polyangiitis (2013) (0)
- Autoantibodies against the murine homolog of Wegener’s autoantigen (proteinase 3) are pathogenic in vivo. (2004) (0)
- Vasculitis 265. Cryoglobulinemic Vasculitis Secondary to Hepatitis C Infection: Is Prediction of Disease Severity Feasible? (2011) (0)
- SAT0012 DETECTION OF CIRCULATING PR3-SPECIFIC B CELLS IN PATIENTS WITH ACTIVE ANCA-ASSOCIATED VASCULITIS (2019) (0)
- FREQUENCY AND LOCATION OF TRACHEOBRONCHIAL LESIONS IN WEGENER GRANULOMATOSIS (2008) (0)
- OP0137 Auto-reactive b cells escape peripheral tolerance checkpoints in patients with pr3-anca associated vasculitis (2017) (0)
- Comparative evaluation of four commercial enzyme immunoassays for auto-antibodies to proteinase 3 (1997) (0)
- OP0058 Using Mass Spectrometry To Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in Anca-Associated Vasculitis (2016) (0)
- Reply (2016) (0)
- Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial (2023) (0)
- Hypoxia and Diffuse Pulmonary Infiltrates in an Immunosuppressed Patient With Vasculitis (2016) (0)
- SAT0370 Antineutrophil Cytoplasmic Antibody (ANCA) Type and Body Mass Index in Anca-Associated Vasculitis (2016) (0)
- The Survival of Patients With Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody–associated Vasculitis (2021) (0)
- VASCULITIS | Microscopic Polyangiitis (2006) (0)
- Collaborative Management of Multi-System Diseases: New Developments and Treatment Strategies (2014) (0)
- Drs. Stone and Specks reply (2010) (0)
- P2_19 High Bartonella Seroprevalence in Proteinase 3-Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (2017) (0)
- Maintenance of Remission and Risk of Relapse in Myeloperoxidase-Positive ANCA-Associated Vasculitis with Kidney Involvement (2022) (0)
- Rituximab or Cyclophosphamide for ANCA-Associated Vasculitis? (2012) (0)
- Anti-proteinase 3 Antibodies Augment Monocyte Activation and May Alter Monocyte Phenotype (2023) (0)
- Hypothyroidism in Vasculitis. (2021) (0)
- Proteinase 3-specific autoantibodies from patients with Wegener's granulomatosis do not recognize recombinant murine proteinase 3 and are inappropriate triggers of experimental vasculitis in mice (1997) (0)
- THU0310 CASE–CONTROL SEROPREVALENCE STUDY ON THE ASSOCIATION BETWEEN BARTONELLA INFECTION AND ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS (2020) (0)
- New etiopathogenic knowledge, or politics? Comment on the article by Falk et al Reply (2011) (0)
- SAT0217 EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: CLINICAL PREDICTORS OF LONG-TERM ASTHMA SEVERITY (2019) (0)
- Recurrent acquired ANCA-positive agranulocytosis after cocaine exposure: A chronic disease? (2013) (0)
- Animal models of vasculitis (2016) (0)
- Clinical role of C-ANCA testing (1990) (0)
- Comparison of patient self-reported data to physician-reported data in eosinophilic granulomatosis with polyangiitis (Preprint) (2021) (0)
- Airway Involvement in Wegener's Granulomatosis Vlassis S. Polychronopoulos, Udaya B.S. Prakash (2007) (0)
- 053. CLINICAL UTILITY OF SERIAL MEASUREMENTS OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES TARGETING PROTEINASE 3 IN ANCA-ASSOCIATED VASCULITIS (2019) (0)
- Constitutive and induced forms of membrane-bound proteinase 3 interact with antineutrophil cytoplasmic antibodies and promote immune activation of neutrophils. (2023) (0)
- 035. CANDIDATE BIOMARKERS IN ANCA-ASSOCIATED VASCULITIS IDENTIFIED USING A PROTEOMIC APPROACH (2019) (0)
- FRI0487 Serum interleukin-6 levels in antineutrophil cytoplasmic antibody-associated vasculitis (2018) (0)
- Neutrophil extracellular trap formation in anti-neutrophil cytoplasmic antibody-associated and large-vessel vasculitis. (2023) (0)
- Advances in Management of Diffuse Alveolar Hemorrhage in ANCA-Associated Vasculitis (2016) (0)
- SAT0236 RELATIONSHIP BETWEEN RITUXIMAB CONCENTRATION AND AUTOANTIBODY LEVELS IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY ASSOCIATED VASCULITIS (2019) (0)
- Treatment of Idiopathic Pulmonary Hemosiderosis with Rituximab (0)
- 190. DETECTION OF CIRCULATING PR3-SPECIFIC B CELLS IN PATIENTS WITH ACTIVE ANCA-ASSOCIATED VASCULITIS (2019) (0)
- THU0040 PROTEINASE 3-REACTIVE B CELL RECONSTITUTION AFTER TREATMENT WITH RITUXIMAB FOR ANCA-ASSOCIATED VASCULITIS (2020) (0)
- Subtle modifications of a PR3-ANCA ELISA affect assay performance. (2006) (0)
- B-Cell Depletion By Rituximab Affects the Distribution of Effector Th-Cell Subsets in Patients with ANCA Associated Vasculitis (2017) (0)
- OP0320 Determinants of rituximab pharmacokinetics and clinical outcomes in patients with anca-associated vasculitis (2017) (0)
- 290. ASTHMA CONTROL IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS TREATED WITH RITUXIMAB (2019) (0)
- Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients Receiving B-Cell Targeted Therapy (2022) (0)
- POS0244 ASSOCIATION OF PROTEINASE 3 GENE (PRTN3) Val119Ile POLYMORPHISM (SNP rs351111) WITH RISK OF RELAPSE AMONG HOMOZYGOUS PATIENTS WITH PR3 ANCA-ASSOCIATED VASCULITIS (2022) (0)
- EXHALED NITRIC OXIDE IN WEGENER'S GRANULOMATOSIS (2008) (0)
- Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis (2022) (0)
- Vitamin D status in ANCA-associated vasculitis (2023) (0)
- AB0511 INTERNATIONAL CONSENSUS ON ANCA TESTING AND INTERPRETATION BEYOND SYSTEMIC VASCULITIS (2020) (0)
- OP0130 Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: a phase iii randomised, placebo-controlled trial (2017) (0)
- Extended Follow-up of Treatment with Rituximab Versus Cyclophosphamide for Remission-Induction of ANCA-Associated Vasculitis (2011) (0)
- Reply: Further Progress in Understanding Fibrosing Mediastinitis. (2015) (0)
- THU0309 NONLINEAR PHARMACOKINETICS OF RITUXIMAB IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY ASSOCIATED VASCULITIS (2019) (0)
- An Unusual Cause Of Chronic Cough And Halitosis (2010) (0)
- Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism (2023) (0)
- Urine eosinophil‐derived neurotoxin declines following mepolizumab treatment in subjects with Eosinophilic Granulomatosis with Polyangiitis: 877 (2019) (0)
- Asthma In Churg Strauss Syndrome: Severity And Characteristics (2011) (0)
- 284. RITUXIMAB VERSUS CYCLOPHOSPHAMIDE FOR CENTRAL NERVOUS SYSTEM INVOLVEMENT OF ANCA-ASSOCIATED VASCULITIS: A RETROSPECTIVE STUDY (2019) (0)
- Increased Severity of Asthma in Atopic Patients with Eosinophilic Granulomatosis with Polyangiitis (2018) (0)
- Wegener's Granulomatosis Human Proteinase 3, the Autoantigen of Mapping of Conformational Epitopes on (2010) (0)
- SAT0369 Weight Gain in Anca-Associated Vasculitis Is Independent of Glucocorticoid Dosing (2016) (0)
- Bradyrhizobium enterica in Cord Colitis Syndrome (2013) (0)
- Ocular manifestations of ANCA-associated vasculitis. (2022) (0)
- Off-Label Use of Benralizumab for Severe Eosinophilic Granulomatosis with Polyangiitis (2019) (0)
- Clinical value of commonly measured laboratory tests in eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (2013) (0)
- Tumor necrosis factor alpha blockade as therapy for sarcoidosis: comment on the article by Ulbricht et al. (2004) (0)
- Collagen VI mRNA expression during wound healing (1992) (0)
- Reply (2017) (0)
- Serum biomarkers during relapsing disease in eosinophilic granulomatosis with polyangiitis (2013) (0)
- Reply (2017) (0)
- Macrophage Stimulating 1 Receptor (2011) (0)
- Naproxen-induced Lichen Planus Bullosus (1999) (0)
- An Unusual Case of Disseminated Blastomycosis Presenting with Hoarseness and Odynophagia (2021) (0)
- OP0236 Risk of cardiovascular disease and venous thromboembolism among patients with incident anca-associated vasculitis: a 20 year population-based cohort study (2018) (0)
- Opponent's comments. (2015) (0)
- 138. DIFFUSE ALVEOLAR HEMORRHAGE, PULMONARY NODULES AND INFILTRATES IN GRANULOMATOSIS POLYANGIITIS AND MICROSCOPIC POLYANGIITIS. A COHORT STUDY OF 736 PATIENTS (2019) (0)
- Circulating markers of vascular injury and angiogenesis in ANCA-AAV (2011) (0)
- Biologic response modifiers for granulomatosis with polyangiitis (Wegener's): from promise to reality (2013) (0)
- Microscopic polyangiitis in the setting of usual interstitial pneumonia (2013) (0)
- Rituximab in Obliterative Bronchiolitis Associated with Sjorgen's Syndrome (2020) (0)
- MO01 EFFECT OF TELMISARTAN IN ADDITION TO ANGIOTENSIN CONVERTING ENZYME INHIBITORS ON MORTALITY AND MORBIDITY IN HAEMODIALYSIS PATIENTS WITH CHRONIC HEART FAILURE: A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (2005) (0)
- 55-year-old man with purpura and foot pain. (2008) (0)
- A REVIEW OF NECROTIZING GRANULOMAS (2007) (0)
- What you should know about PR 3-ANCA Conformational requirements of proteinase 3 ( PR 3 ) for enzymatic activity and recognition by PR 3-ANCA (2015) (0)
- Is avacopan better than prednisone for respiratory ANCA-associated vasculitis outcomes? (2022) (0)
- The role of macrophage migration inhibitory factor in the pathogenesis of granulomatosis with polyangiitis (2017) (0)
- Proprotein Convertase Subtilisin/Kexin Type 6 (PCSK6) is a likely antigenic target in membranous nephropathy and nonsteroidal anti-inflammatory drug use. (2023) (0)
- RELENT project. 190. DETECTION OF CIRCULATING PR3-SPECIFIC B CELLS IN PATIENTS WITH ACTIVE ANCA-ASSOCIATED VASCULITIS (2019) (0)
- Circulating PR3-Specific B Cells in Patients with Active ANCA-Associated Vasculitis (2019) (0)
- PLEX in AAV-GN: insights from the meta-analysis results and impact on remission induction treatment recommendations (2022) (0)
- Pulmonary Vasculitis and Alveolar Hemorrhage (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Ulrich Specks?
Ulrich Specks is affiliated with the following schools:
